6533b82cfe1ef96bd128eca4

RESEARCH PRODUCT

Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria

Tyler J. FraumAnup S. ShettyRichard TsaiRoberto CannellaAllan TsungMaverick LeblancKathryn J. FowlerMuhammad NaeemJaquelyn FleckensteinDaniel R. LudwigAmber SalterAlessandro FurlanAmir A. Borhani

subject

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularPopulationSensitivity and SpecificityCholangiocarcinoma03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineData SystemsHumanseducationneoplasmsAgedRetrospective Studieseducation.field_of_studyLI-RADS Hepatocellular carcinomaHepatologymedicine.diagnostic_testbusiness.industryFatty liverLiver NeoplasmsGastroenterologyReproducibility of ResultsMagnetic resonance imagingRetrospective cohort studyHepatitis CHepatitis C Chronicmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesFatty Liver030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemalebusinessTomography X-Ray ComputedSettore MED/36 - Diagnostica Per Immagini E Radioterapia

description

Abstract Background Hepatocellular carcinoma (HCC) can be diagnosed using imaging criteria in patients at high-risk for HCC, according to Liver Imaging Reporting and Data System (LI-RADS) guidelines. The aim of this study was to determine the diagnostic performance and inter-rater reliability (IRR) of LI-RADS v2018 for differentiating HCC from non-HCC primary liver carcinoma (PLC), in patients who are at increased risk for HCC but not included in the LI-RADS ‘high-risk’ population. Methods This retrospective HIPAA-compliant study included a 10-year experience of pathologically-proven PLC at two liver transplant centers, and included patients with non-cirrhotic hepatitis C infection, non-cirrhotic non-alcoholic fatty liver disease, and fibrosis. Two readers evaluated each lesion and assigned an overall LI-RADS diagnostic category, additionally scoring all major, LR-M, and ancillary features. Results The final study cohort consisted of 27 HCCs and 104 non-HCC PLC in 131 patients. The specificity of a ‘definite HCC’ designation was 97% for reader 1 and 100% for reader 2. The IRR was fair for overall LI-RADS category and substantial for most major features. Conclusion In a population at increased risk for HCC but not currently included in the LI-RADS ‘high-risk’ population, LI-RADS v2018 demonstrated very high specificity for distinguishing pathologically-proven HCC from non-HCC PLC.

10.1016/j.hpb.2019.04.007https://hdl.handle.net/10447/584024